Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

100.0%

9 terminated/withdrawn out of 9 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

4 of 0 completed trials have results

Key Signals

4 with results8 terminated

Enrollment Performance

Analytics

Phase 2

5(55.6%)

Phase 1

3(33.3%)

Phase 3

1(11.1%)

9Total

Phase 2(5)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05313009Phase 1Terminated

Tarlox and Sotorasib in Patients With KRAS G12C Mutations

Role: collaborator

NCT04979442Phase 3Terminated

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

Role: lead

NCT05012397Phase 2Terminated

Milademetan in Advanced/Metastatic Solid Tumors

Role: lead

NCT05932667Phase 2Terminated

Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer

Role: collaborator

NCT06090318Phase 1Withdrawn

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Role: lead

NCT05758818Phase 1Terminated

A Study of Milademetan Administration on Cardiac Repolarization in Healthy Subjects

Role: lead

NCT03805841Phase 2Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions

Role: lead

NCT02454842Phase 2Terminated

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Role: lead

NCT02449681Phase 2Terminated

Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Role: lead

All 9 trials loaded